London, 3 May 2018 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), announces that its wholly owned US subsidiary West-Ward Pharmaceuticals Corp. (West-Ward), has launched Methotrexate for Injection, USP in a 1g preservative-free presentation and Methotrexate Injection, USP 50mg/2mL, 2 mL vials.
3 May 2018
Product, Press Release
According to IQVIA, US sales of Methotrexate for Injection, USP, 1g and Methotrexate Injection, USP, 50mg/2mL, were approximately $13 million in the 12 months ending March 2018.
Riad Mechlaoui, Chief Executive Officer Injectables, said, “We are pleased to launch Methotrexate for Injection, USP and Methotrexate Injection, USP, helping reduce the shortage of this product in the US market. Our continued progress in executing our injectables pipeline demonstrates our strong R&D, regulatory and manufacturing capabilities.”